{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T19:16:03Z","timestamp":1791486963742,"version":"4.3.4"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,12,10]]},"DOI":"10.7759\/cureus.32383","type":"journal-article","created":{"date-parts":[[2022,12,10]],"date-time":"2022-12-10T18:15:59Z","timestamp":1670696159000},"source":"Crossref","is-referenced-by-count":2,"title":["Ponatinib-Induced Cerebrovascular Accident (CVA)"],"prefix":"10.7759","author":[{"given":"Farhan","family":"Azad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahua","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clive J","family":"Miranda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Gravina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29383","article-title":"New insights into the pathophysiology and therapy of adult acute lymphoblastic leukemia","volume":"121","author":"Jabbour E","year":"2015","unstructured":"Jabbour E, O'Brien S, Konopleva M, Kantarjian H. New insights into the pathophysiology and therapy of adult acute lymphoblastic leukemia. Cancer. 2015, 121:2517-28. 10.1002\/cncr.29383","journal-title":"Cancer"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-012-0247-7","article-title":"Philadelphia-positive acute lymphoblastic leukemia: current treatment options","volume":"14","author":"Liu-Dumlao T","year":"2012","unstructured":"Liu-Dumlao T, Kantarjian H, Thomas DA, O'Brien S, Ravandi F. Philadelphia-positive acute lymphoblastic leukemia: current treatment options. Curr Oncol Rep. 2012, 14:387-94. 10.1007\/s11912-012-0247-7","journal-title":"Curr Oncol Rep"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-01-242750","article-title":"How I treat Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"116","author":"Fielding AK","year":"2010","unstructured":"Fielding AK. How I treat Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 2010, 116:3409-17. 10.1182\/blood-2010-01-242750","journal-title":"Blood"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2014.11.009","article-title":"The BCR-ABL inhibitor ponatinib inhibits platelet immunoreceptor tyrosine-based activation motif (ITAM) signaling, platelet activation and aggregate formation under shear","volume":"135","author":"Loren CP","year":"2015","unstructured":"Loren CP, Aslan JE, Rigg RA, et al.. The BCR-ABL inhibitor ponatinib inhibits platelet immunoreceptor tyrosine-based activation motif (ITAM) signaling, platelet activation and aggregate formation under shear. Thromb Res. 2015, 135:155-60. 10.1016\/j.thromres.2014.11.009","journal-title":"Thromb Res"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-2329","article-title":"Targeting FGFR signaling in cancer","volume":"21","author":"Touat M","year":"2015","unstructured":"Touat M, Ileana E, Postel-Vinay S, Andr\u00e9 F, Soria JC. Targeting FGFR signaling in cancer. Clin Cancer Res. 2015, 21:2684-94. 10.1158\/1078-0432.CCR-14-2329","journal-title":"Clin Cancer Res"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-021-04507-x","article-title":"Clinical outcomes in patients with Philadelphia chromosome-positive leukemia treated with ponatinib in routine clinical practice-data from a Belgian registry","volume":"100","author":"Devos T","year":"2021","unstructured":"Devos T, Havelange V, Theunissen K, et al.. Clinical outcomes in patients with Philadelphia chromosome-positive leukemia treated with ponatinib in routine clinical practice-data from a Belgian registry. Ann Hematol. 2021, 100:1723-32. 10.1007\/s00277-021-04507-x","journal-title":"Ann Hematol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.11406\/rinketsu.61.1018","article-title":"Management of vascular adverse events during tyrosine kinase inhibitors in patients with chronic myeloid leukemia  (Article in Japanese)","volume":"61","author":"Takaku T","year":"2020","unstructured":"Takaku T. Management of vascular adverse events during tyrosine kinase inhibitors in patients with chronic myeloid leukemia  (Article in Japanese). Rinsho Ketsueki. 2020, 61:1018-27. 10.11406\/rinketsu.61.1018","journal-title":"Rinsho Ketsueki"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S189391","article-title":"Ponatinib: a novel multi-tyrosine kinase inhibitor against human malignancies","volume":"12","author":"Tan FH","year":"2019","unstructured":"Tan FH, Putoczki TL, Stylli SS, Luwor RB. Ponatinib: a novel multi-tyrosine kinase inhibitor against human malignancies. Onco Targets Ther. 2019, 12:635-45. 10.2147\/OTT.S189391","journal-title":"Onco Targets Ther"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2021.11.012","article-title":"The outcomes of ponatinib therapy in patients with chronic myeloid leukemia resistant or intolerant to previous tyrosine kinase inhibitors, treated in Poland within the donation program","volume":"22","author":"Sacha T","year":"2022","unstructured":"Sacha T, Szczepanek E, Dumnicka P, et al.. The outcomes of ponatinib therapy in patients with chronic myeloid leukemia resistant or intolerant to previous tyrosine kinase inhibitors, treated in Poland within the donation program. Clin Lymphoma Myeloma Leuk. 2022, 22:405-15. 10.1016\/j.clml.2021.11.012","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-09-739086","article-title":"Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial","volume":"132","author":"Cortes JE","year":"2018","unstructured":"Cortes JE, Kim DW, Pinilla-Ibarz J, et al.. Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial. Blood. 2018, 132:393-404. 10.1182\/blood-2016-09-739086","journal-title":"Blood"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2012.11.022","article-title":"Early superficial temporal artery to middle cerebral artery bypass in acute ischemic stroke","volume":"115","author":"Lee SB","year":"2013","unstructured":"Lee SB, Huh PW, Kim DS, Yoo DS, Lee TG, Cho KS. Early superficial temporal artery to middle cerebral artery bypass in acute ischemic stroke. Clin Neurol Neurosurg. 2013, 115:1238-44. 10.1016\/j.clineuro.2012.11.022","journal-title":"Clin Neurol Neurosurg"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)00080-2","article-title":"Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial","volume":"17","author":"Lipton JH","year":"2016","unstructured":"Lipton JH, Chuah C, Guerci-Bresler A, et al.. Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial. Lancet Oncol. 2016, 17:612-21. 10.1016\/S1470-2045(16)00080-2","journal-title":"Lancet Oncol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.104075","article-title":"Early onset hypercholesterolemia induced by the 2nd-generation tyrosine kinase inhibitor nilotinib in patients with chronic phase-chronic myeloid leukemia","volume":"99","author":"Rea D","year":"2014","unstructured":"Rea D, Mirault T, Cluzeau T, Gautier JF, Guilhot F, Dombret H, Messas E. Early onset hypercholesterolemia induced by the 2nd-generation tyrosine kinase inhibitor nilotinib in patients with chronic phase-chronic myeloid leukemia. Haematologica. 2014, 99:1197-203. 10.3324\/haematol.2014.104075","journal-title":"Haematologica"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021012082","article-title":"Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial","volume":"138","author":"Cortes J","year":"2021","unstructured":"Cortes J, Apperley J, Lomaia E, et al.. Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial. Blood. 2021, 138:2042-50. 10.1182\/blood.2021012082","journal-title":"Blood"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/126984-ponatinib-induced-cerebrovascular-accident-cva","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:45:01Z","timestamp":1707507901000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/126984-ponatinib-induced-cerebrovascular-accident-cva"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,10]]},"references-count":14,"URL":"https:\/\/doi.org\/10.7759\/cureus.32383","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12,10]]}}}